



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10748,764
Filing Date	December 30, 2003
First Named Inventor	Madhav S. Thakur et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-957DIV

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
J		JANSSEN_CILAG FARMACEUTICA, LDA, "Topamax (summary of Product Characteristics of Topiramate, approved by the Portuguese Health Authorities)", 20 ABR. 2004, Comunica No. 19, p. 11-12	XX
		EUROPEAN COMMISSION, Directorate General III - Industry Pharmaceuticals and Cosmetics, "Guidelines - Medicinal Products for Human Use, Quality and Biotechnology", The Rules Governing Medicinal Product in European Union, Vol. 3A, pp. 143-151, 1998	
		EUROPEAN COMMISSION, Directorate General III - Industry Pharmaceuticals and Cosmetics, "Guidelines - Medicinal Products for Human Use, Quality and Biotechnology", The Rules Governing Medicinal Product in European Union, Vol. 3A, pp. 127-141, 1998	
		SIMPOSIUM TERAPEUTICO, Enciclopedia de Especialidades Farmaceuticas Portuguesas "Monography of TOPAMAX", pp. 1015-1055, 2001	XX
		SIMPOSIUM TERAPEUTICO, Enciclopedia de Especialidades Farmaceuticas Portuguesas, "Monography of TOPAMAX", pp. 1015-1017, 2002	XX
		SIMPOSIUM TERAPEUTICO, Enciclopedia de Especialidades Farmaceuticas Portuguesas, "Monography of TOPAMAX", pp. 974-977, 2003	XX
Y		SIMPOSIUM TERAPEUTICO, Enciclopedia de Especialidades Farmaceuticas Portuguesas, "Monography of TOPAMAX", pp. 986-989, 2004	XX

Examiner Signature	<i>[Signature]</i>	Date Considered	1/12/05
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.